Search results
Lupus erythematosus (LE) is an autoimmune disease characterized by a wide range of cutaneous (CLE) and/or systemic (SLE) symptoms. CLE can be seen with or without SLE (i.e. as part of a systemic disease or as a separate entity with primarily cutaneous manifestations), and the latter may present or develop cutaneous manifestations.
30 sie 2010 · In the first part of the review, topical agents and first-line systemic treatment options for cutaneous lupus erythematosus were discussed whereas in the second part, recent information on efficacy, dosage, and side effects for further systemic treatment options are described in detail.
25 cze 2021 · The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of cutaneous lupus erythematosus (CLE) in the presence or absence of systemic lupus erythematosus (SLE) in adults, young people and children. The document aims to:
Class 2–4 topical glucocorticoids are the treatment of choice for cutaneous lupus erythematosus (CLE). A randomized, controlled study has shown that fluocinonide 0.05 % is more effective than hydrocortisone 1 % [ 1 ].
1 gru 2023 · Lupus treatments include nonsteroidal anti-inflammatory drug (NSAID), antimalarial drugs, corticosteroids, immunosuppressants, and biologics. NSAIDs, such as naproxen (Aleve) or ibuprofen (Advil), may be used to symptoms such as pain or swelling.
4 kwi 2020 · Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials. Summary. CLE is a group of complex and heterogenous diseases.
20 gru 2016 · Abstract. Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used ‘off-label’.
